1. Home
  2. PLBC vs FULC Comparison

PLBC vs FULC Comparison

Compare PLBC & FULC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Plumas Bancorp

PLBC

Plumas Bancorp

HOLD

Current Price

$61.42

Market Cap

426.2M

Sector

Finance

ML Signal

HOLD

Logo Fulcrum Therapeutics Inc.

FULC

Fulcrum Therapeutics Inc.

HOLD

Current Price

$3.77

Market Cap

467.8M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
PLBC
FULC
Founded
1980
2015
Country
United States
United States
Employees
N/A
N/A
Industry
Finance Companies
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
426.2M
467.8M
IPO Year
2002
2019

Fundamental Metrics

Financial Performance
Metric
PLBC
FULC
Price
$61.42
$3.77
Analyst Decision
Buy
Buy
Analyst Count
3
8
Target Price
$57.67
$16.38
AVG Volume (30 Days)
53.1K
1.5M
Earning Date
04-15-2026
04-27-2026
Dividend Yield
2.60%
N/A
EPS Growth
N/A
N/A
EPS
2.79
N/A
Revenue
N/A
N/A
Revenue This Year
$25.59
N/A
Revenue Next Year
$5.15
N/A
P/E Ratio
$22.10
N/A
Revenue Growth
N/A
N/A
52 Week Low
$39.89
$2.83
52 Week High
$63.74
$15.74

Technical Indicators

Market Signals
Indicator
PLBC
FULC
Relative Strength Index (RSI) 57.46 49.08
Support Level $51.85 $3.44
Resistance Level $63.74 $4.02
Average True Range (ATR) 1.35 0.15
MACD -0.21 0.05
Stochastic Oscillator 46.94 69.32

Price Performance

Historical Comparison
PLBC
FULC

About PLBC Plumas Bancorp

Plumas Bancorp provides banking products and services in Northeastern California and Northwestern Nevada, offering a range of deposit products for commercial and retail customers, including checking, savings, money market accounts, time deposits, retirement accounts, and sweep accounts for businesses and public entities, along with digital banking services such as mobile and internet banking, remote deposit, and electronic funds transfers, as well as other customary banking services. Its loan portfolio comprises commercial real estate, commercial and industrial, consumer, agricultural, residential real estate, and construction and land development loans, and the company generates its revenue from loans and investment securities, with additional income from service fees.

About FULC Fulcrum Therapeutics Inc.

Fulcrum Therapeutics Inc is a clinical-stage biopharmaceutical company focused on developing small molecules for genetically defined rare diseases. Its product candidate, Pociredir, is an oral small molecule designed to induce fetal hemoglobin (HbF) and is in clinical development for sickle cell disease (SCD). The company completed dosing in the Phase 1b PIONEER trial evaluating pociredir in adults with SCD and reported clinical data showing clinically relevant HbF induction and improvements in markers of hemolysis and anemia. The company has also generated a pipeline of clinical-stage and pre-clinical programs targeting the root causes of rare genetic diseases.

Share on Social Networks: